Home >> Cell Cycle >> CDK >>

CDK Inhibitors

Cat.No. Product Name Information Publication Customer Review
S1116 PD 0332991 (Palbociclib) HCl PD 0332991 is a highly selective inhibitor of CDK4/cyclin D1 and CDK6/cyclin D2 with IC50 of 11 nM and 16 nM, respectively. (5)
S2768 Dinaciclib (SCH727965) Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM, respectively.
S1524 AT7519 AT7519 is a novel multi-CDK inhibitor for CDK1/cyclin B, CDK2/Cyclin A, CDK3/Cyclin E, CDK4/Cyclin D1, CDK5/p35 and CDK6/Cyclin D3 with IC50 of 210 nM, 47 nM, 360 nM, 100 nM, 13 nM and 170 nM, respectively. (2)
S2679 Flavopiridol (Alvocidib) HCl Flavopiridol competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM, and CDK7 with IC50 of 300 nM. (2)
S1153 Roscovitine (Seliciclib, CYC202) Roscovitine (Seliciclib, CYC202, R-roscovitine) is a potent and selective CDK inhibitor for Cdc2/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p53 with IC50 of 0.65 μM, 0.7 μM, 0.7 μM and 0.16 μM, respectively. (3)
S1145 SNS-032 (BMS-387032) SNS-032 is a novel, potent and selective CDK inhibitor of CDK2, CDK7 and CDK9 with IC50 of 38 nM, 62 nM and 4 nM, respectively. (1)
S1249 JNJ-7706621 JNJ-7706621 is a potent and multi-target inhibitor for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, Aurora A and Aurora B with IC50 of 9 nM, 4 nM, 3 nM, 11 nM and 15 nM, respectively.
S8058 P276-00 p276-00 is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively.
S7047 BAY 1000394 BAY 1000394 is an orally bioavailable CDK inhibitor.
S1579 PD 0332991 (Palbociclib) Isethionate PD 0332991 (Palbociclib) Isethionate is the isethionate of PD 0332991, a highly specific inhibitor of CDK4 and CDK6 with IC50 of 11 nM and 16 nM, respectively.
S2014 BMS-265246 BMS265246 is a potent and selective CDK inhibitor for CDK1/cyclin B and CDK2/cyclin E with IC50 of 6 nM and 9 nM, respectively.
S2751 Milciclib (PHA-848125) PHA-848125 is a potent, ATP-competitive cyclin A/CDK2 inhibitor with IC50 of 45 nM.
S2742 PHA-767491 PHA-767491 is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.
S2735 SCH 900776 SCH 900776 is a selective Chk1 inhibitor with IC50 of 3 nM and also inhibits CDK2 with IC50 of 160 nM.
S2688 R547 R547 is a potent and selective CDK inhibitor with Ki and IC50 of 1-3 nM and 80 nM respectively.
S2670 A-674563 A-674563 inhibits Akt1, PKA and CDK2 with Ki of 11 nM, 16 nM and 46 nM, respectively.
S2621 AZD5438 AZD5438 is a potent inhibitor of CDK1, CDK2 and CDK9 with IC50 of 16 nM, 6 nM, and 20 nM, respectively.
S1572 BS-181 HCl BS-181 is a highly selective CDK inhibitor for CDK7 with IC50 of 21 nM.
S1487 PHA-793887 PHA-793887 is a novel and potent inhibitor of CDK2, CDK5 and CDK7 with IC50 of 8 nM, 5 nM and 10 nM, respectively. (1)
S1230 Flavopiridol (Alvocidib) Flavopiridol (Alvocidib, HMR-1275, L86-8275) is a pan-CDK inhibitor targeting CDK1, CDK2, CDK4, CDK5, CDK6 and CDK9 with IC50 of 30 nM, 170 nM, 100 nM, 170 nM, 80 nM and 20 nM, respectively. (3)